SEC Form 4 · accession 0001817160-26-000010
Nurix Therapeutics, Inc. · NRIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gwenn Hansen
Officer — Chief Scientific Officer
Period of report
Jun 25, 2026
Accepted (ET)
Jun 25, 2026 · 6:49 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001549595
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 25, 2026 | S | 5,394 | $20.00 | D | 115,005 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.